CVRX
Neutral signalScored 2026-08-23 Drivers: fundamentals. Moteurs : fondamentaux.
Research, not advice.
À propos
CVRx, Inc.
- Nom
- CVRx, Inc.
- Secteur
- Healthcare
- Industrie
- Medical - Devices
- Bourse
- NASDAQ
- Capitalisation
- $37.8M
- Employés
- 223
- PDG
- Kevin Hykes
- Site web
- https://www.barostim.com
- Marché
- CERSMASSNNOXOMIPRQRQTRX
CVRx, Inc. is a commercial-stage medical technology company focused on innovating, producing, and bringing to market neuromodulation solutions designed for individuals battling cardiovascular diseases. Its principal offering, Barostim, is an advanced neuromodulation device specifically indicated to ameliorate symptoms for patients diagnosed with heart failure characterized by reduced ejection fraction, often referred to as systolic heart failure. The company employs a diverse distribution strategy, leveraging its internal sales force, alongside sales agents and independent distributors, to reach markets across the United States, Germany, the wider European continent, and other global territories. Incorporated in 2000, CVRx, Inc. is headquartered in Minneapolis, Minnesota.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
ACHAT TOTAL: 26223 titres (~76432 USD) VENTE TOTALE: 1309 titres (~3338 USD)
- Insiders
- Binkowski Brent
- Total bought
-
$76,432
Avg buy (VWAP, 90d window) $2.91 vs last close —
- Total sold
-
$3,338
Avg sell (VWAP, 90d window) $2.55 vs last close —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$3,338 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-08-13
- Last synced
-
2026-08-25 17:08:49
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-08-13 | Binkowski Brent | Buy · P | 26,223 | $2.91 | $76,432 | Form 4 |
| 2026-08-12 | Binkowski Brent | Sell · S · 10b5-1 | 1,309 | $2.55 | $3,338 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Neutral signalScored 2026-08-23 Drivers: fundamentals. Moteurs : fondamentaux.
CVRX combines deeply distressed fundamentals (persistent operating losses, negative ROE/ROIC, 400+ day cash conversion cycle) with an extremely weak catalyst profile dominated by active securities fraud investigations…
The first sentence of the analysis written for CVRX on 2026-08-23 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Neutral signal
Drivers: fundamentals. Moteurs : fondamentaux.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Supports a bullish reading. Open-market purchases outweigh sales
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Unavailable or mixed. Current ratio 7.63 · operating margin -90% — readings disagree
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 85.3% | 83.8% | 84.1% | 77.8% | 72.1% | |
| Ebit Margin | -83.8% | -108.2% | -99.9% | -183.2% | -312.7% | |
| Ebitda Margin | -82.5% | -107.0% | -98.6% | -181.3% | -311.4% | |
| Operating Profit Margin | -90.5% | -116.0% | -109.7% | -189.3% | -199.2% | |
| Pretax Profit Margin | -94.1% | -116.8% | -104.5% | -183.9% | -329.8% | |
| Continuous Operations Profit Margin | -94.1% | -116.9% | -104.8% | -184.4% | -330.5% | |
| Net Profit Margin | -94.1% | -116.9% | -104.8% | -184.4% | -330.5% | |
| Bottom Line Profit Margin | -94.1% | -116.9% | -104.8% | -184.4% | -330.5% | |
| Current Ratio | 7.633 | 12.062 | 14.254 | 15.193 | 25.575 | |
| Quick Ratio | 6.716 | 10.937 | 12.857 | 14.332 | 24.918 | |
| Solvency Ratio | -0.803 | -0.952 | -1.036 | -2.603 | -6.512 | |
| Cash Ratio | 5.685 | 9.843 | 11.517 | 13.130 | 24.047 | |
| Price To Earnings Ratio | -3.480 | -4.781 | -15.799 | -9.084 | -5.796 | |
| Price To Earnings Growth Ratio | 0.151 | -0.144 | 10.638 | 2.130 | -0.031 | |
| Forward Price To Earnings Growth Ratio | 0.151 | -0.144 | 10.638 | 2.130 | -0.031 | |
| Price To Earnings Diluted Ratio | -3.480 | -4.781 | -15.799 | -9.084 | -5.796 | |
| Price To Earnings Diluted Growth Ratio | 0.151 | -0.144 | 10.638 | 2.130 | -0.031 | |
| Price To Book Ratio | 4.710 | 4.029 | 8.570 | 3.447 | 1.736 | |
| Price To Sales Ratio | 3.269 | 5.582 | 16.565 | 16.749 | 19.439 | |
| Price To Free Cash Flow Ratio | -4.545 | -7.068 | -16.432 | -8.679 | -8.764 | |
| Price To Operating Cash Flow Ratio | -4.610 | -7.314 | -16.681 | -8.818 | -9.138 | |
| Debt To Assets Ratio | 0.485 | 0.378 | 0.266 | 0.057 | 0.000 | |
| Debt To Equity Ratio | 1.292 | 0.710 | 0.403 | 0.065 | 0.000 | |
| Debt To Capital Ratio | 0.564 | 0.415 | 0.287 | 0.061 | 0.000 | |
| Long Term Debt To Capital Ratio | 0.561 | 0.409 | 0.278 | 0.058 | 0.000 | |
| Financial Leverage Ratio | 2.665 | 1.878 | 1.517 | 1.144 | 1.045 | |
| Working Capital Turnover Ratio | 0.546 | 0.459 | 0.359 | 0.173 | 0.129 | |
| Operating Cash Flow Ratio | -3.016 | -3.637 | -4.962 | -5.277 | -4.694 | |
| Operating Cash Flow Sales Ratio | -0.709 | -0.763 | -0.993 | -1.899 | -2.127 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.014 | 1.035 | 1.015 | 1.016 | 1.043 | |
| Debt Service Coverage Ratio | -8.018 | -12.497 | -21.611 | -247.582 | -18.338 | |
| Interest Coverage Ratio | -8.798 | -13.530 | -23.959 | -257.739 | -11.703 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -0.791 | -0.776 | -1.275 | -6.023 | 0.000 | |
| Capital Expenditure Coverage Ratio | -69.259 | -28.761 | -66.025 | -62.302 | -23.442 | |
| Dividend Paid And Capex Coverage Ratio | -69.259 | -28.761 | -66.025 | -62.302 | -23.442 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -3.429 | -4.204 | -15.258 | -6.805 | -2.742 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 85.3% | ▲1.6% | ▲4.7% |
| Ebit Margin | -83.8% | ▲24.4% | ▲73.7% |
| Ebitda Margin | -82.5% | ▲24.5% | ▲73.7% |
| Operating Profit Margin | -90.5% | ▲25.5% | ▲50.4% |
| Pretax Profit Margin | -94.1% | ▲22.7% | ▲71.7% |
| Continuous Operations Profit Margin | -94.1% | ▲22.8% | ▲72.0% |
| Net Profit Margin | -94.1% | ▲22.8% | ▲72.0% |
| Bottom Line Profit Margin | -94.1% | ▲22.8% | ▲72.0% |
| Current Ratio | 7.633 | ▼-4.429 | ▼-7.310 |
| Quick Ratio | 6.716 | ▼-4.221 | ▼-7.236 |
| Solvency Ratio | -0.803 | ▲0.149 | ▲1.578 |
| Cash Ratio | 5.685 | ▼-4.158 | ▼-7.159 |
| Price To Earnings Ratio | -3.480 | ▲1.301 | ▲4.308 |
| Price To Earnings Growth Ratio | 0.151 | ▲0.295 | ▼-2.398 |
| Forward Price To Earnings Growth Ratio | 0.151 | ▲0.295 | ▼-2.398 |
| Price To Earnings Diluted Ratio | -3.480 | ▲1.301 | ▲4.308 |
| Price To Earnings Diluted Growth Ratio | 0.151 | ▲0.295 | ▼-2.398 |
| Price To Book Ratio | 4.710 | ▲0.680 | ▲0.211 |
| Price To Sales Ratio | 3.269 | ▼-2.312 | ▼-9.052 |
| Price To Free Cash Flow Ratio | -4.545 | ▲2.523 | ▲4.553 |
| Price To Operating Cash Flow Ratio | -4.610 | ▲2.703 | ▲4.702 |
| Debt To Assets Ratio | 0.485 | ▲0.107 | ▲0.248 |
| Debt To Equity Ratio | 1.292 | ▲0.582 | ▲0.798 |
| Debt To Capital Ratio | 0.564 | ▲0.148 | ▲0.298 |
| Long Term Debt To Capital Ratio | 0.560 | ▲0.151 | ▲0.299 |
| Financial Leverage Ratio | 2.665 | ▲0.787 | ▲1.015 |
| Working Capital Turnover Ratio | 0.546 | ▲0.087 | ▲0.213 |
| Operating Cash Flow Ratio | -3.016 | ▲0.621 | ▲1.301 |
| Operating Cash Flow Sales Ratio | -0.709 | ▲0.054 | ▲0.589 |
| Free Cash Flow Operating Cash Flow Ratio | 1.014 | ▼-0.020 | ▼-0.010 |
| Debt Service Coverage Ratio | -8.018 | ▲4.479 | ▲53.591 |
| Interest Coverage Ratio | -8.798 | ▲4.732 | ▲54.348 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | -0.791 | ▼-0.015 | ▲0.982 |
| Capital Expenditure Coverage Ratio | -69.259 | ▼-40.497 | ▼-19.301 |
| Dividend Paid And Capex Coverage Ratio | -69.259 | ▼-40.497 | ▼-19.301 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -3.429 | ▲0.775 | ▲3.058 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $185.2M | $286.3M | $650.9M | $376.3M | $253.4M | |
| Enterprise value | $160.3M | $230.8M | $590.9M | $277.2M | $111.3M | |
| EV / Sales | 2.83x | 4.50x | 15.04x | 12.34x | 8.54x | |
| EV / Op. cash flow | -3.99x | -5.90x | -15.14x | -6.50x | -4.01x | |
| EV / Free cash flow | -3.93x | -5.70x | -14.92x | -6.39x | -3.85x | |
| EV / EBITDA | -3.43x | -4.20x | -15.26x | -6.80x | -2.74x | |
| Net debt / EBITDA | 0.53x | 1.01x | 1.55x | 2.43x | 3.50x | |
| Current ratio | 7.63x | 12.06x | 14.25x | 15.19x | 25.57x | |
| Income quality | 0.75x | 0.65x | 0.95x | 1.03x | 0.64x | |
| Graham net-net | $1 | $3 | $3 | $5 | $7 | |
| Tax burden | 100.0% | 100.1% | 100.4% | 100.3% | 100.2% | |
| Interest burden | 112.3% | 107.9% | 104.6% | 100.4% | 105.4% | |
| Working capital | $88.3M | $119.1M | $104.2M | $114.8M | $145.2M | |
| Invested capital | $91.5M | $122.6M | $107.3M | $116.8M | $146.6M | |
| Return on assets | -50.9% | -44.9% | -35.8% | -33.2% | -28.2% | |
| Operating ROA | -43.0% | -47.9% | -35.9% | -30.7% | -23.9% | |
| Return on tangible assets | -50.9% | -44.9% | -35.8% | -33.2% | -28.2% | |
| Return on equity | -135.6% | -84.4% | -54.2% | -37.9% | -29.5% | |
| Return on invested capital | -56.0% | -48.4% | -40.1% | -36.3% | -17.7% | |
| Return on capital employed | -56.0% | -48.5% | -40.1% | -36.4% | -17.7% | |
| Earnings yield | -28.8% | -20.9% | -6.3% | -11.0% | -17.0% | |
| Free cash flow yield | -22.0% | -14.1% | -6.1% | -11.5% | -11.4% | |
| Capex / Op. cash flow | -1.4% | -3.5% | -1.5% | -1.6% | -4.3% | |
| Capex / Depreciation | 76.7% | 219.9% | 113.2% | 166.3% | 704.2% | |
| Capex / Sales | 1.0% | 2.7% | 1.5% | 3.0% | 9.1% | |
| SG&A / Sales | 156.2% | 178.0% | 164.2% | 222.7% | 213.7% | |
| R&D / Sales | 19.7% | 21.7% | 29.6% | 44.3% | 57.5% | |
| Stock comp / Sales | 19.5% | 37.1% | 16.0% | 17.3% | 14.7% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 69d | 66d | 70d | 89d | 72d | |
| Days payables outstanding | 168d | 113d | 110d | 126d | 51d | |
| Operating cycle | 605d | 596d | 711d | 597d | 461d | |
| Cash conversion cycle | 436d | 483d | 601d | 472d | 410d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▼-35.3%EV / Sales ▼-37.1%EV / EBITDA ▲+18.4%EV / Op. cash flow ▲+1.906Earnings yield ▼-0.078
Profitability
Return on equity ▼-0.512Return on assets ▼-0.059Return on invested capital ▼-0.076Return on capital employed ▼-0.075Operating ROA ▲+0.048Income quality ▲+0.101Tax burden ▼-0.001
Efficiency
Days sales outstanding ▲+2.762Days payables outstanding ▲+55.254Operating cycle ▲+8.533Cash conversion cycle ▼-46.721Capex / Sales ▼-0.016R&D / Sales ▼-0.021
Balance-sheet strength
Current ratio ▼-4.429Net debt / EBITDA ▼-0.478Working capital ▼-30721000.000Invested capital ▼-31174000.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▼-26.9%EV / Sales ▼-66.9%EV / EBITDA ▼-25.1%EV / Op. cash flow ▲+0.025Earnings yield ▼-0.118
Profitability
Return on equity ▼-1.060Return on assets ▼-0.226Return on invested capital ▼-0.383Return on capital employed ▼-0.383Operating ROA ▼-0.191Income quality ▲+0.110Tax burden ▼-0.002
Efficiency
Days sales outstanding ▼-2.964Days payables outstanding ▲+117.196Operating cycle ▲+143.985Cash conversion cycle ▲+26.789Capex / Sales ▼-0.081R&D / Sales ▼-0.379
Balance-sheet strength
Current ratio ▼-17.942Net debt / EBITDA ▼-2.966Working capital ▼-56859000.000Invested capital ▼-55163000.000Intangibles / Total assets n/a
Employee count
Peer market caps
Recent news
- 2026-08-19 HAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, Encourages CVRx Inc. (CVRX) Investors with Substantial Losses to Contact Firm: Investigating Potential Securities Fraud Following 59% Stock Drop SAN FRANCISCO, Aug. 19, 2026 /PRNewswire/ -- Hagens Berman, a national shareholder rights litigation firm, announces it has opened an investigation into CVRx Inc. (NASDAQ: CVRX) regarding potential violations of federal securities laws. The investigation follows disclosures of a U.S. Department of Justice Civil Investigative Demand ("CID"), severe cuts to revenue guidance, commercial sales force disruption, and the sudden termination of the company''s Chief Revenue Officer.
- 2026-08-18 CVRx, Inc. Investigated For Securities Fraud; Block & Leviton Encourages Investors Who Have Lost Money to Contact the Firm Boston, Massachusetts--(Newsfile Corp. - August 18, 2026) - Block & Leviton is investigating CVRx, Inc. (NASDAQ: CVRX) for potential securities law violations. Investors who have lost money in their CVRx, Inc. investment should contact the firm to learn more about how they might recover those losses.
- 2026-08-13 HAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, Encourages CVRx Inc. (CVRX) Investors with Substantial Losses to Contact Firm: Investigating Potential Securities Fraud Following 59% Stock Drop SAN FRANCISCO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Hagens Berman, a national shareholder rights litigation firm, announces it has opened an investigation into CVRx Inc. (NASDAQ: CVRX) regarding potential violations of federal securities laws. The investigation follows disclosures of a U.S. Department of Justice Civil Investigative Demand (“CID”), severe cuts to revenue guidance, commercial sales force disruption, and the sudden termination of the company''s Chief Revenue Officer.
- 2026-08-13 CVRX ALERT: Securities Fraud Investigation by Block & Leviton Could Allow CVRx, Inc. Investors to Recover Losses Boston, Massachusetts--(Newsfile Corp. - August 13, 2026) - Block & Leviton is investigating CVRx, Inc. (NASDAQ: CVRX) for potential securities law violations. Investors who have lost money in their CVRx, Inc. investment should contact the firm to learn more about how they might recover those losses.
- 2026-08-13 CVRx Eyes Barostim Growth as Coverage Gains and BENEFIT-HF Trial Launches CVRx NASDAQ: CVRX outlined its efforts to expand adoption of its Barostim therapy for heart failure patients, emphasizing sales-force execution, payer coverage progress and a large post-market clinical trial during Canaccord Genuity''s 46th Annual Growth Conference.
- 2026-08-11 Securities Fraud Investigation Into CVRx, Inc. (CVRX) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of CVRx, Inc. (“CVRx” or the “Company”) (NASDAQ: CVRX) on behalf of investors concerning the Company''s possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON CVRX, INC. (CVRX), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On August 6, 2026, CVRx reported second quarter earnings, including that "In May of 2.
- 2026-08-11 CVRx, Inc. (CVRX) Shareholders Who Lost Money -- Contact Law Offices of Howard G. Smith About Securities Fraud Investigation Law Offices of Howard G. Smith announces an investigation on behalf of CVRx, Inc. (âCVRxâ or the âCompanyâ) (NASDAQ: [url="]CVRX[/url]) investors concer
- 2026-08-11 CVRx, Inc. (CVRX) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of CVRx, Inc. (“CVRx” or the “Company”) (NASDAQ: CVRX) investors concerning the Company''s possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN CVRX, INC. (CVRX), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@h.
- 2026-08-10 Securities Fraud Investigation Into CVRx, Inc. (CVRX) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of CVRx, Inc. (“CVRx” or the “Company”) (NASDAQ: CVRX) investors concerning the Company''s possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON CVRX, INC. (CVRX), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. What Happened? On August 6, 2026, CVR.
- 2026-08-10 CVRX INVESTIGATION: CVRx, Inc. Investigated for Securities Fraud by Block & Leviton; Investors Should Contact the Firm to Possibly Recover Losses BOSTON, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Block & Leviton is investigating CVRx, Inc. (Nasdaq: CVRX) for potential securities law violations. Investors who have lost money in their CVRx, Inc. investment should contact the firm to learn more about how they might recover those losses.